SCHEDULE: Citadel Entities Disclose Significant Boundless Bio Stake
Beneficial Ownership Disclosure (Schedule 13G)
Citadel Advisors, Citadel Securities, and Kenneth Griffin have disclosed beneficial ownership of Boundless Bio, Inc. common stock, with Griffin holding 6.4% of the outstanding shares.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively reported beneficial ownership of 830,936 shares of Boundless Bio, Inc. common stock, representing 3.7% of the class.
- Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC collectively reported beneficial ownership of 602,452 shares, representing 2.7% of the class.
- Kenneth Griffin, through his control over the Citadel entities, reported beneficial ownership of 1,433,388 shares, constituting 6.4% of Boundless Bio, Inc.'s common stock.
- All reported shares are held with shared voting and shared dispositive power; no reporting person holds sole voting or sole dispositive power.
- The percentages are based on 22,385,611 shares outstanding as of October 31, 2025, as reported in Boundless Bio's Form 10-Q filed on November 5, 2025.
Sentiment
Score: 7
Explanation: The filing indicates a significant institutional investment by Citadel and Kenneth Griffin, which is generally viewed positively as a vote of confidence in the company. While it's a passive stake, it can attract further investor attention.
Positives
- A significant institutional investor like Citadel, and its founder Kenneth Griffin, taking a stake can be viewed as a vote of confidence in Boundless Bio, Inc.'s future prospects.
- Increased institutional ownership can enhance liquidity and investor interest in the stock.
Future Outlook
NA
Industry Context
The disclosure of a significant stake by a prominent hedge fund and market maker like Citadel, and its principal Kenneth Griffin, in a company like Boundless Bio, Inc. (likely a biotechnology or life sciences firm given its name and typical CUSIP issuer profile for a recent IPO) often signals institutional interest in the sector or specific company's potential. Such filings are common as institutional investors cross ownership thresholds.
Comparison to Industry Standards
- The reported ownership percentages are standard for Schedule 13G filings, which are required when beneficial ownership exceeds 5% for passive investors.
- Citadel's investment strategy often involves diverse holdings across various sectors, and a 6.4% stake is a notable, but not controlling, position for a passive investment.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by a reputable firm like Citadel may increase investor confidence and potentially lead to increased trading volume and share price appreciation.
- Company Management: May view this as validation of their strategy and potentially open doors for future institutional engagement.
Key Dates
| Date | Description |
|---|---|
| 2025-10-31 | Date of shares outstanding calculation (22,385,611 shares) according to issuer's Form 10-Q. |
| 2025-11-05 | Date Boundless Bio, Inc. filed its Form 10-Q with the SEC. |
| 2025-11-26 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-12-04 | Date of filing of this Schedule 13G statement and the date for the holdings of the reporting persons. |
Keywords
Boundless Bio, Citadel, Kenneth Griffin, Beneficial Ownership, Schedule 13G, Institutional Investment, Common Stock, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.